LyfPlus provides medical services and technology solutions to hospitals, including telehealth, e-pharmacies, and AI clinical support. Self-described as re-imagining future technologies in healthcare.

LyfPlus

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Linda Avey

Paul Cusenza

Anne Wojcicki

23andMe Holding Co.

GoodRx provides information on prescription prices, coupons, and pharmacy services. This includes tools to compare medication prices and access discounts, as self-described.

GoodRx

Livongo is a health technology company that specializes in chronic disease management, providing support for hypertension, weight management, diabetes prevention, and mental health needs through smart connected devices and personalized coaching.

Metric
Company Name	LyfPlus	23	GoodRx	Livongo
Symbol		ME
MSH ID	COM:LYFPLUS	COM:23ANDME	COM:GOODRX	COM:LIVONGO
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Health Technology	Medical - Diagnostics & Research	Healthcare	Healthcare & Health Services
Country	US	US	US	US
Stage			Private Equity Round	Series E
Employee Count		560		117
Website	lyfplus.com	23andme.com	goodrx.com	livongo.com
LinkedIn		23andme		livongo
Founders

Metric
Market Cap	225.52M
Enterprise Value
Monthly Web Traffic	6.55M	22.66M
Web Traffic Growth	-0.06	0.11
Valuation
Raised Capital		100M	105.00M

Metric
Revenue		219.64M
Revenue (LTM)
Revenue (NTM)
Gross Profit		99.38M
EBITDA		-291.88M
Operating Income		-321.36M
Net Income		-666.70M
EPS		-1.40
Diluted EPS		-1.40
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.45
Operating Profit Margin		-2.17
EBITDA Margin		-1.33
Net Profit Margin		-2.10
Return on Equity		-0.87
Return on Assets		-0.86
Return on Capital Employed		-1.16

COM:LYFPLUS

LyfPlus

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.93
P/B Ratio		0.50
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		13.37
EV Multiple		-3.85

Metric
Days Sales Outstanding		2.03
Days Payables Outstanding		21.21
Days Inventory Outstanding		48.94
Operating Cycle		97.37
Cash Conversion Cycle		62.09
Asset Turnover		0.56

Metric
Operating Cash Flow		-155.53M
Free Cash Flow		-165.19M
Cash Flow to Debt		-1.75
Operating Cash Flow/Sales		-0.65
Free Cash Flow Yield		-0.50

Metric
Cash & Equivalents		217.89M
Accounts Receivable		-1.43M
Inventory		12.46M
Goodwill
Debt to Capitalization		0.34
Debt to Assets		0.10
Current Ratio		2.93
Quick Ratio		1.87

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.49
R&D to Revenue		0.87
SG&A to Revenue		0.53